Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III trial of BAY 94-9027 (damoctocog alfa pegol) in severe hemophilia A
2011-005210-11Phase 2Completed
- Sponsor
- Bayer
- Start
- May 2012
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of damoctocog alfa pegol in hemophilia A (2 arms), sponsored by Bayer. Primary endpoint: Efficacy in prevention and treatment of bleeding. Started May 2012; status: completed.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2011-005210-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005210-11.